Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MucusIBD

Financiado

Cerrado

Innovative mucus secretion stimulation for inflammation control in Inflammatory...

Innovative mucus secretion stimulation for inflammation control in Inflammatory Bowel Disease Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, are chronic, debilitating conditions affecting millions worldwide. There is currently no cure for IBD, only treatments aimed at inducing long last... ver más

31/03/2026

BIU

Presupuesto desconocido

Líder del proyecto

BAR ILAN UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-01

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada hace 10 meses

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

BIU

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EPIMACASE THE ROLE OF ELASTASE ELASTASE INHIBITOR IN DIALOG BETWEEN IN... 246K€ Cerrado

BFU2012-35999 PAPEL DE LAS CELULAS EPITELIALES INTESTINALES Y SUS PROGENIT... 94K€ Cerrado

CrUCCial Novel diagnostic and therapeutic approach to inflammatory bo... 2M€ Cerrado

MuRe Sorting and export of mucins. 165K€ Cerrado

MUCO-IMMUN MUCOBIOME MEDIATED IMMUNE PATHWAYS IN INFLAMMATORY BOWEL DIS... 166K€ Cerrado

GUTMAPS Cellular cartography of the intestine in health and inflamma... 188K€ Cerrado

Duración del proyecto: 17 meses Fecha Inicio: 2024-10-01
Fecha Fin: 2026-03-31

Líder del proyecto

BAR ILAN UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, are chronic, debilitating conditions affecting millions worldwide. There is currently no cure for IBD, only treatments aimed at inducing long lasting remission. These treatment options act mainly by inhibiting the patient’s immune system, leaving patients immunocompromised, and come with a high annual direct cost. Even with advanced treatment, most IBD patients will require surgery during their lifetimes. Thus, more affordable treatment option which are not focused on immune suppression are needed. While the etiology of IBDs is not clear, it is thought that breakdown of gut barrier function is a major driver of chronic intestinal inflammation. Indeed, penetrance of luminal microbes into the mucus layer which covers the intestinal epithelium is a hallmark of IBDs. This penetrance and contact of microbes with the host’s immune system drives a proinflammatory response and prevents tissue healing. While performing our ERC-funded research project we found a way to induce excess intestinal mucus secretion in mice. We found this excess mucus secretion protected mice from development of colitis in a model of IBD. We also uncovered the mechanism which controls intestinal mucus secretion and discovered a cheap and reproducible way to pharmacologically induce excess mucus secretion using a bile acid.Our goal is to determine whether pharmacologically inducing intestinal mucus production in preclinical mouse models of IBD can induce and sustain remission. The project's methodology encompasses preclinical trials utilizing three distinct mouse models to rigorously test the efficacy and safety of our innovation. A comprehensive market analysis, informed by stakeholders including healthcare professionals and patient advocacy groups, will guide the development process, ensuring the therapeutic approach meets the real-world needs of IBD patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores